INC Research (INCR) Rating Reiterated by Credit Suisse Group
INC Research (NASDAQ:INCR)‘s stock had its “buy” rating restated by Credit Suisse Group in a research report issued to clients and investors on Thursday. They presently have a $52.00 target price on the stock. Credit Suisse Group’s price target would suggest a potential upside of 25.91% from the stock’s current price.
Other analysts have also recently issued reports about the stock. BidaskClub upgraded shares of INC Research from a “hold” rating to a “buy” rating in a research report on Wednesday. KeyCorp restated a “buy” rating and set a $50.00 target price on shares of INC Research in a research report on Thursday. Zacks Investment Research upgraded shares of INC Research from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a research report on Wednesday, September 27th. TheStreet cut shares of INC Research from a “b-” rating to a “c” rating in a research report on Monday, December 18th. Finally, Mizuho began coverage on shares of INC Research in a research report on Thursday, September 21st. They set a “neutral” rating and a $57.00 target price on the stock. One analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $50.78.
Shares of INC Research (NASDAQ:INCR) traded down $2.50 during mid-day trading on Thursday, reaching $41.30. 1,958,200 shares of the company’s stock traded hands, compared to its average volume of 1,219,100. The stock has a market cap of $4,310.00, a PE ratio of -72.46, a P/E/G ratio of 1.35 and a beta of 1.09. INC Research has a 1-year low of $33.60 and a 1-year high of $61.10. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.27 and a current ratio of 1.27.
A number of large investors have recently modified their holdings of INCR. Lee Thomas H Partners LP bought a new position in INC Research during the 3rd quarter valued at about $1,316,644,000. BlackRock Inc. grew its holdings in INC Research by 82.3% during the 2nd quarter. BlackRock Inc. now owns 6,461,899 shares of the company’s stock valued at $378,020,000 after purchasing an additional 2,917,605 shares during the last quarter. Janus Henderson Group PLC bought a new position in INC Research during the 2nd quarter valued at about $99,424,000. State Street Corp grew its holdings in INC Research by 112.8% during the 2nd quarter. State Street Corp now owns 1,769,353 shares of the company’s stock valued at $103,508,000 after purchasing an additional 937,864 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in INC Research by 1,337.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 598,039 shares of the company’s stock valued at $31,277,000 after purchasing an additional 556,439 shares during the last quarter. Institutional investors own 99.50% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “INC Research (INCR) Rating Reiterated by Credit Suisse Group” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/01/05/inc-research-incr-rating-reiterated-by-credit-suisse-group.html.
INC Research Company Profile
INC Research Holdings, Inc is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.
Receive News & Ratings for INC Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research and related companies with MarketBeat.com's FREE daily email newsletter.